GAM Holding’s Myriad Genetics MYGN Stock Holding History

GAM Holding’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-14,637	Closed	-$433K	–	942
2018 Q1	$433K	Sell	14,637 -16,237	-53%	-$549K	0.02%	669
2017 Q4	$1.06M	Buy	+30,874	New	+$1.04M	0.03%	567
2017 Q2	–	Sell	-132,339	Closed	-$2.54M	–	1053
2017 Q1	$2.54M	Buy	132,339 +12,000	+10%	+$213K	0.04%	454
2016 Q4	$2.01M	Buy	120,339 +10,053	+9%	+$182K	0.04%	479
2016 Q3	$2.27M	Buy	110,286 +95,286	+635%	+$2.42M	0.04%	447
2016 Q2	$459K	Buy	+15,000	New	+$521K	0.01%	752
2014 Q4	–	Sell	-20,000	Closed	-$771K	–	1135
2014 Q3	$771K	Hold	20,000	–	–	0.01%	758
2014 Q2	$778K	Hold	20,000	–	–	0.01%	749
2014 Q1	$684K	Sell	20,000 -67,500	-77%	-$2.09M	0.01%	758
2013 Q4	$1.84M	Buy	87,500 +20,000	+30%	+$506K	0.03%	465
2013 Q3	$1.59M	Buy	67,500 +25,360	+60%	+$720K	0.03%	526
2013 Q2	$1.13M	Buy	+42,140	New	+$1.22M	0.02%	505

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GAM Holding's MYGN Position: Q2 2018 in Review

GAM Holding sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 14,637 shares — an estimated $433K sold.

GAM Holding first reported a position in MYGN in Q2 2013 and held it in 12 quarters. The position peaked at $2.54M in Q1 2017. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

GAM Holding reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
GAM Holding sold 14,637 Myriad Genetics shares in Q2 2018, an estimated $433K.
GAM Holding first reported a position in Myriad Genetics in Q2 2013 and held it in 12 quarters.
GAM Holding's Myriad Genetics position peaked at $2.54M in Q1 2017.
258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on GAM Holding's 13F filing for Q2 2018, filed 9 Aug 2018.